Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Sponsor: Pierre Fabre Medicament
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Official title: A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2021-08-04
Completion Date
2029-03-30
Last Updated
2025-12-24
Healthy Volunteers
No
Interventions
KIN-2787
KIN-2787 will be administered orally twice daily in 28-day cycles
KIN-2787 and binimetinib
Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles
Locations (50)
The Angeles Clinic
Los Angeles, California, United States
UCLA
Los Angeles, California, United States
University of California San Diego, Moores Cancer Center
San Diego, California, United States
University of California San Francisco
San Francisco, California, United States
Stanford Cancer Center
Stanford, California, United States
Sarah Cannon Research Institute Denver
Denver, Colorado, United States
Mayo Clinic - Florida
Jacksonville, Florida, United States
Sarah Cannon Research Institute - Florida Cancer Specialists
Orlando, Florida, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Atlantic Health
Morristown, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
NYU Langone
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Sarah Cannon Research Institute-Tennessee Oncology
Nashville, Tennessee, United States
MD Anderson
Houston, Texas, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Calvary Mater Hospital Newcastle
Waratah, New South Wales, Australia
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
Tasman Health Care
Southport, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Harbin Medical University Cancer Hospital
Haerbin, Heilongjiang, China
Linyi Cancer Hospital
Linyi, Shandong, China
Beijing University Cancer Hospital
Beijing, China
The Shanghai Pulmonary Hospital
Shanghai, China
Institut Bergonie
Bordeaux, France
Centre Francois Baclesse
Caen, France
CHU de Lille
Lille, France
Centre Leon Berard
Lyon, France
APHM-CHU La Timone
Marseille, France
CHU Nantes-Hotel Dieu
Nantes, France
CHU de Nice - Hôpital Archet 2
Nice, France
APHP - Hôpital St Louis
Paris, France
Hospices Civiles de Lyon - Hôpital Lyon Sud
Pierre-Bénite, France
CHU de Poitiers
Poitiers, France
Oncopole Claudius Regaud
Toulouse, France
Gustave Roussy
Villejuif, France
Istituto Nazionale dei Tumori Fondazione G. Pascale
Naples, Italy
Arance
Barcelona, Spain, Spain
NEXT Quirónsalud Madrid
Madrid, Spain, Spain
H. Regional de Málaga
Málaga, Spain, Spain
H. Virgen Macarena
Seville, Spain, Spain
Berrocal
Valencia, Spain, Spain
Hospital Quiron Dexeus
Barcelona, Spain
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain
START Madrid
Madrid, Spain
Hospital General Gregorio Marañón
Madrid, Spain
INCLIVA (Hospital Clinico de Valencia)
Valencia, Spain
National Taiwan University Hospital
Taipei, Taiwan